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Metabolic reprogramming has long been viewed as an
important component of malignant transformation.
Recent years have defined a large number of mechan-
isms by which oncogene-directed perturbations of signal
transduction regulate intermediary metabolism, and
conversely, by which metabolites themselves influence
gene expression and other dimensions of systems biol-
ogy. However, there is still little agreement as to the
breadth of metabolic programs that can support cancer
cell growth, and more importantly, about which of the
myriad metabolic activities observed in culture models
of cancer cell proliferation are relevant to the survival
and growth of tumors in vivo. I will discuss approaches
to address these two challenges. First, I will discuss
ongoing efforts to link functional metabolic pathway
choices with oncogenotypes using systematic analysis of
large panels of cancer cell lines. Second, I will describe
efforts to probe metabolism in living tumors from
humans and mice, using a combination of stable isotope
tracing and other methods.
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